Catalent (NYSE:CTLT) was downgraded by research analysts at BidaskClub from a “buy” rating to a “hold” rating in a research report issued to clients and investors on Tuesday, November 14th.
A number of other equities research analysts have also commented on the company. Zacks Investment Research lowered Catalent from a “buy” rating to a “hold” rating in a research report on Friday, September 1st. Bank of America restated a “buy” rating and issued a $40.00 price objective (up previously from $38.00) on shares of Catalent in a research report on Tuesday, August 29th. William Blair restated an “ourperform” rating on shares of Catalent in a research report on Tuesday, August 29th. ValuEngine upgraded Catalent from a “hold” rating to a “buy” rating in a research report on Thursday, September 7th. Finally, Piper Jaffray Companies restated a “buy” rating and issued a $45.00 price objective on shares of Catalent in a research report on Tuesday, August 29th. Four analysts have rated the stock with a hold rating and six have assigned a buy rating to the company’s stock. The company has a consensus rating of “Buy” and an average price target of $44.25.
Shares of Catalent (NYSE CTLT) traded down $0.99 during trading on Tuesday, reaching $38.80. 612,803 shares of the company’s stock were exchanged, compared to its average volume of 894,161. Catalent has a fifty-two week low of $23.03 and a fifty-two week high of $43.39. The company has a debt-to-equity ratio of 2.01, a current ratio of 2.91 and a quick ratio of 2.49. The company has a market capitalization of $5,154.93, a P/E ratio of 27.13, a PEG ratio of 2.49 and a beta of 1.42.
In other news, Director Uwe Roehrhoff acquired 7,500 shares of Catalent stock in a transaction that occurred on Tuesday, November 21st. The stock was purchased at an average cost of $39.22 per share, with a total value of $294,150.00. The purchase was disclosed in a filing with the SEC, which is accessible through this hyperlink. 1.70% of the stock is currently owned by corporate insiders.
Several institutional investors and hedge funds have recently modified their holdings of CTLT. Janus Henderson Group PLC acquired a new stake in shares of Catalent during the 2nd quarter worth about $239,629,000. BlackRock Inc. increased its position in shares of Catalent by 15.2% during the 2nd quarter. BlackRock Inc. now owns 17,512,661 shares of the company’s stock worth $614,695,000 after purchasing an additional 2,316,849 shares during the last quarter. Eagle Asset Management Inc. increased its position in shares of Catalent by 290.9% during the 3rd quarter. Eagle Asset Management Inc. now owns 1,153,710 shares of the company’s stock worth $47,636,000 after purchasing an additional 858,600 shares during the last quarter. AJO LP acquired a new stake in shares of Catalent during the 2nd quarter worth about $26,130,000. Finally, Macquarie Group Ltd. increased its position in shares of Catalent by 60.2% during the 2nd quarter. Macquarie Group Ltd. now owns 1,786,764 shares of the company’s stock worth $62,715,000 after purchasing an additional 671,429 shares during the last quarter. 99.44% of the stock is owned by institutional investors and hedge funds.
Catalent Company Profile
Catalent, Inc provides delivery technologies and development solutions for drugs, biologics, and consumer and animal health products. Its segments include Softgel Technologies, Drug Delivery Solutions and Clinical Supply Services. The Softgel Technologies segment is engaged in the formulation, development and manufacturing of prescription and consumer health soft capsules or softgels.
Receive News & Ratings for Catalent Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Catalent Inc. and related companies with our FREE daily email newsletter.